JP Morgan upgraded Hengrui Medicine (01276.HK) from Hold to Overweight and trimmed its target price to HK$68 from HK$70. The bank said the sharp share-price decline reflects macro headwinds—notably heightened U.S.-China geopolitical tensions and broad institutional de-risking of H-share healthcare—rather than a material weakening of fundamentals. At current levels, JP Morgan sees valuation as understating an improving earnings trajectory, rapidly expanding pipeline value and BD-related revenue,

JP Morgan upgraded Hengrui Medicine (01276.HK) from Hold to Overweight and trimmed its target price to HK$68 from HK$70. The bank said the sharp share-price decline reflects macro headwinds—notably heightened U.S.-China geopolitical tensions and broad institutional de-risking of H-share healthcare—rather than a material weakening of fundamentals. At current levels, JP Morgan sees valuation as understating an improving earnings trajectory, rapidly expanding pipeline value and BD-related revenue, but warned U.S. rules could constrain future China-origin licensing deals and increase volatility.